Psychedelic Science Research,
what lands in your inbox each week:
- ๐7 fresh studies
- ๐plain-language summaries
- โ direct links to original studies
- ๐ top journal indicators
- ๐ weekly delivery
- ๐งโโ๏ธalways free
some of our latest newsletters:
(select one to read it below)
Psilocybin's antidepressant effects lasted 12 months in 126 treatment-resistant patients
This week brought the largest and longest follow-up study of any psychedelic trial to date, plus new insights into how these compounds affect everything from personality to pain processing.
๐ Psilocybin's Depression Benefits Lasted a Full Year
- 126 patients with treatment-resistant depression showed sustained improvement 12 months after receiving one or two 25mg psilocybin doses with psychotherapy
- Depression scores dropped by an average of 7.74 points from baseline at the 12-month markโa clinically meaningful improvement that held steady from the 6-month assessment
- Patients who restarted traditional antidepressants during follow-up had depression scores that were 3.79 points higher, suggesting psilocybin's effects may reduce the need for ongoing medication
Why it matters: This represents the most complete long-term data on any psychedelic therapy, showing that brief psilocybin treatment can produce lasting benefits that persist well beyond the drug's immediate effects.
Key Findings
๐ง Psilocybin Changes DNA Methylation in Alcohol Patients
- The first genome-wide study of psilocybin's epigenetic effects found significant DNA methylation changes in 37 patients with alcohol use disorder
- One gene (TLE4) showed particularly strong methylation changes (p = 1.1e-7), while network analysis revealed modules linked to neuroplasticity and immune function
- Changes in depression and hopelessness scores correlated with specific methylation patterns, suggesting epigenetic mechanisms may underlie psilocybin's therapeutic effects
โ ๏ธ Psychedelics Trigger Mania in 5.8% to 30% of Users
- A meta-analysis of 23 studies found psychedelic-induced mania rates varied dramaticallyโfrom 5.8% in controlled clinical trials to 30% in people with existing bipolar disorder
- Registry data from 7,478 people showed only 4% transitioned to bipolar disorder after psychedelic use, with no clear evidence that psychedelics specifically caused the transition
- Higher risks appeared in people with bipolar I disorder, family history of mood disorders, and unsupervised psychedelic use
๐ญ Psilocybin's Social Effects Differ Dramatically by Sex in Mice
- Female mice showed immediate increases in huddling and hypothermia after 1.5 mg/kg psilocybin, while males showed no comparable acute effects
- At 24 hours, males became more social toward cage-mates and showed blunted dopamine responses that lasted 7 days
- By day 7, females preferred familiar over novel companions and showed prolonged dopamine release during familiar social interactions
๐ Study Challenges the Idea That Psychedelics Always Boost Flexibility
- A comprehensive review found mixed evidence for psychedelics enhancing cognitive flexibility, with several cases showing impairment rather than improvement
- Researchers propose that psychedelics may initially enhance learning from rewards (leading to perseveration) but later improve learning from negative outcomes
- The timing of these effects may explain why insights reached during psychedelic experiences are often held so strongly
๐ฉบ Swiss Doctors Report Real-World Psychedelic Therapy Practices
- 41 Swiss physicians providing legal psychedelic therapy primarily treat depression, anxiety, PTSD, and chronic pain using psilocybin (85%), MDMA (71%), and LSD (66%)
- 90% always play music during sessions, and emergency medication is used in only 2.4% of sessions on average
- 42% provide both individual and group therapy sessions, with only 9% reporting they never use co-sitters for support
๐ฌ Blinding Integrity Fails in Psychedelic Studies
- In a study of 120 healthy volunteers, participants correctly identified psilocybin, MDMA, or methylphenidate (active placebo) at rates well above chance
- Psilocybin showed the highest rates of functional unblinding, MDMA moderate levels, and methylphenidate the lowest
- Methylphenidate worked better as an active placebo for MDMA studies than for psilocybin studies, but overall blinding remained insufficient
Implications
This week's research reveals both the promise and complexity of psychedelic medicine. While long-term benefits appear robust, the field faces challenges around sex differences, timing of effects, patient selection, and research methodology that will need addressing as these therapies move toward broader clinical use.
Science is the only real news.
The rest is just drama ๐ฐ
And nowadays, we see that drama everywhere.
Drama sells ads, ads sell products, and my attention sells to the highest bidder.
Drama media is junk food for the mind.
A quick rush, hard to avoid, but little nutritional value.
The brain wants broccoli ๐ง ๐ฅฆ
And look, it's not that science never makes the news.
But think about when it doesโdoes the news really understand the science it reports on?
Like it or not, AI exists now.
And it happens to be a huge science nerdโฆ ๐ญ๐ค
โฆwith a superpowerโฆ
...unlike an average science nerd, AI can explain it simply.
I built OpenScience to make the constant stream of new studies accessible to anyone.
To free science from academic jargon and tiny-fonted PDFs.
OpenScience is a weekly newsletter of 7 compelling studies from the past week in the topic of your choice.
Made simple, digestible, and delightful by AI.
Interested in CRISPR?
The latest Long Covid research?
Psychedelic medicine?
Follow the actual science, as it comes out.
Every study is linked to the original PubMed so you can verify the AI's summary yourself.
Pick a topic, get the weekly email, and give your mind the broccoli it deserves ๐ฅฆ
The real-time unfolding of science is too interesting not to follow.